We are live on ! Find out more
EFM

E Fund Management Portfolio holdings

AUM $3.37B
This Fund
S&P 500
This Quarter Est. Return
+21.94%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.2B
AUM Growth
+$128M
Cap. Flow
+$26.2M
Cap. Flow %
2.17%
Top 10 Hldgs %
56.76%
Holding
362
New
28
Increased
88
Reduced
207
Closed
28

Top Buys

Rank Stock Value
1
TME icon
Tencent Music
TME
+$28.3M
2
LEGN icon
Legend Biotech
LEGN
+$20.2M
3
TCOM icon
Trip.com Group
TCOM
+$16M
4
STAA icon
STAAR Surgical
STAA
+$10.7M
5
ZLAB icon
Zai Lab
ZLAB
+$7.74M

Top Sells

Rank Stock Value
1
BEKE icon
KE Holdings
BEKE
+$21.9M
2
GOOG icon
Alphabet (Google) Class C
GOOG
+$10.8M
3
NIO icon
NIO
NIO
+$10.3M
4
LI icon
Li Auto
LI
+$8.53M
5
BZ icon
Kanzhun
BZ
+$8.18M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 36.91%
2 Technology 25.51%
3 Communication Services 14.94%
4 Healthcare 9.44%
5 Real Estate 3.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
126
DELISTED
Akero Therapeutics
AKRO
$526K 0.04%
+9,604
New +$411K
TMO icon
127
Thermo Fisher Scientific
TMO
$211B
$523K 0.04%
950
-72
-7% -$38.2K
ALT icon
128
Altimmune
ALT
$539M
$515K 0.04%
31,286
+10,646
+52% +$120K
CTAS icon
129
Cintas
CTAS
$82.4B
$513K 0.04%
4,548
-240
-5% -$26K
HZNP
130
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$495K 0.04%
4,346
-2,861
-40% -$238K
EXC icon
131
Exelon
EXC
$48.6B
$492K 0.04%
11,387
-385
-3% -$15.2K
IDXX icon
132
Idexx Laboratories
IDXX
$42.9B
$491K 0.04%
1,203
-161
-12% -$62.5K
RARE icon
133
Ultragenyx Pharmaceutical
RARE
$2.65B
$482K 0.04%
10,398
+725
+7% +$28.5K
CPRX
134
DELISTED
Catalyst Pharmaceutical
CPRX
$480K 0.04%
25,814
-2,011
-7% -$31K
ABT icon
135
Abbott
ABT
$180B
$479K 0.04%
4,364
-384
-8% -$39.8K
KO icon
136
Coca-Cola
KO
$354B
$479K 0.04%
7,535
-347
-4% -$20.9K
PCVX icon
137
Vaxcyte
PCVX
$7.89B
$476K 0.04%
+9,933
New +$390K
ILMN icon
138
Illumina
ILMN
$29.4B
$471K 0.04%
2,393
-199
-8% -$41.2K
EXAS
139
DELISTED
Exact Sciences
EXAS
$469K 0.04%
9,481
-2,237
-19% -$91.4K
RYTM icon
140
Rhythm Pharmaceuticals
RYTM
$7B
$468K 0.04%
16,056
-1,979
-11% -$50.9K
TGTX icon
141
TG Therapeutics
TGTX
$8.58B
$466K 0.04%
39,393
-13,757
-26% -$99.8K
ACAD icon
142
Acadia Pharmaceuticals
ACAD
$4.25B
$464K 0.04%
29,170
+1,763
+6% +$27.6K
SRPT icon
143
Sarepta Therapeutics
SRPT
$1.66B
$463K 0.04%
3,573
-449
-11% -$52K
CTIC
144
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$463K 0.04%
77,101
+1,968
+3% +$10.7K
BCRX icon
145
BioCryst Pharmaceuticals
BCRX
$2.37B
$462K 0.04%
40,255
+4,838
+14% +$60.3K
ROP icon
146
Roper Technologies
ROP
$36.3B
$461K 0.04%
1,066
– –
ROST icon
147
Ross Stores
ROST
$76.6B
$461K 0.04%
3,969
-283
-7% -$28.9K
INSM icon
148
Insmed
INSM
$23.2B
$457K 0.04%
22,897
+3,712
+19% +$71.7K
APH icon
149
Amphenol
APH
$188B
$456K 0.04%
11,986
-32
-0.3% -$1.21K
MRTX
150
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$456K 0.04%
10,055
+4,435
+79% +$287K
4 5
6
7 8

Similar funds

VFCM
Valley Forge Capital Management Miami, Florida $3.38B AUM 15.93% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
DIA
Dana Investment Advisors Waukesha, Wisconsin $3.35B AUM 29.65% 1-Year Est. Return
5NCM
59 North Capital Management Houston, Texas $3.35B AUM 22.14% 1-Year Est. Return
TAM
Troy Asset Management London, United Kingdom $3.35B AUM 11.7% 1-Year Est. Return
CS
CapitalatWork SA Auderghem $3.35B AUM
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
QCG
Quadrant Capital Group Cincinnati, Ohio $3.34B AUM 29.16% 1-Year Est. Return

E Fund Management's Q4 2022 Portfolio in Review

As of Q4 2022, E Fund Management held 362 positions worth $1.2B, up 12% from $1.07B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

E Fund Management's Q4 2022 filing shows 28 new, 88 increased, 207 reduced and 28 closed positions. Its largest new stake was Akero Therapeutics: 9,604 shares worth $526K. The largest sale was KE Holdings, an estimated $21.9M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 37% of assets, up from 34% a quarter earlier, followed by Technology and Communication Services.

  • E Fund Management's largest Q4 2022 buy was Akero Therapeutics: 9,604 shares worth $526K.
  • E Fund Management added most to Tencent Music in Q4 2022, an estimated $28.3M increase.
  • E Fund Management's biggest Q4 2022 reduction was KE Holdings, cutting an estimated $21.9M.
  • E Fund Management fully exited Li Auto in Q4 2022, selling an estimated $8.53M.
  • E Fund Management's ten largest holdings make up 57% of its $1.2B portfolio in Q4 2022.
  • E Fund Management opened 28 new positions and closed 28 in Q4 2022.
  • E Fund Management's portfolio value rose 12% quarter-over-quarter to $1.2B.

Based on E Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.